The Genentech Inc. eye drug Lucentis performed well in a late-stage study of patients with diabetic macular edema — a treatment that could be rejected in the United Kingdom — but the real insight ...
ZURICH, May 4 (Reuters) - Swiss drugmaker Novartis AG said on Wednesday a new study showed that its Lucentis eye drug is safer than cancer drug Avastin for treating macular degeneration. Novartis said ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today two-year data from the Phase III Pagoda and Pavilion studies ...
Ranibizumab implants approved by FDA for DME offer a more convenient treatment schedule, reducing injection frequency significantly. The phase 3 Pagoda study showed noninferior visual acuity with ...
Eye injections of the drug Avastin, used to treat retinal diseases, bring no greater risk of endophthalmitis, a potentially blinding eye infection, than injections with the much more expensive drug ...
ZURICH (Reuters) - Switzerland's Novartis and Roche were fined 444 million euros (403.55 million pounds)by France, after its competition authority said on Wednesday they used abusive practices to push ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results